Tag:
Ligand Pharmaceuticals
Latest Headlines
Latest Headlines
GSK relying on Ph3 strategy in R&D comeback bid
GlaxoSmithKline ($GSK) was one of the first of the Big Pharma companies to concede that its R&D effort needed to be completely revamped. Over the last couple of years GSK responded by breaking
Ligand emerges from recession with strong pipeline
Xconomy has a lengthy profile on Ligand Pharmaceuticals, a San Diego-based developer founded in 1987. After going public in 1992, the developer brought five products to market and, at its peak,
Ligand snaps up CyDex in $35.5M buyout
With one eye on adding revenue to the books and another focused on new delivery technology, San Diego-based Ligand Pharmaceuticals ( $LGND ) has snagged CyDex Pharmaceuticals for $31.2 million in cash
Roche dumps hep C development deal with Ligand
Roche is dumping another development pact. This time the Swiss pharma giant is dropping a deal to develop new hepatitis C drugs with Ligand Pharmaceuticals ( $LGNDD ), according to the UK biotech. The
Ligand Pharma snaps up struggling Metabasis
Less than two months after its CEO announced plans to jump ship, Ligand Pharmaceuticals announced a deal to buy the struggling La Jolla, CA-based Metabasis ( MBRX ) for only $3.2 million in cash--less
Ligand strikes deal to buy struggling Neurogen
Three months after slashing half of its workforce and shelving research work, Neurogen has agreed to be bought out by Ligand Pharmaceuticals for $11 million in stock and the chance to earn millions
Pfizer, Ligand gain European approval for bone drug
San Diego-based Ligand Pharmaceuticals had plenty to cheer about after European regulators approved Pfizer's application to sell Fablyn to women with weak bones. The regulatory win at the European
Ligand inks new development pact with Glaxo
San Diego-based Ligand Pharmaceuticals will pocket a $5 million upfront fee and up to $158 million in development and commercial milestones under a new pact it signed with GlaxoSmithKline covering
Promacta gets FDA approval
The FDA has approved GlaxoSmithKline and Ligand Pharmaceuticals' Promacta (eltrombopag). The drug treats a rare immune condition called thrombocytopenia purpura, in which a patient's immune system
Ligand inks $70M deal for Pharmacopeia
San Diego-based Ligand Pharmaceuticals says it will pay $70 million to acquire Pharmacopeia. The acquisition is a stock-for-stock deal. In addition, Pharmacopeia stockholders will be entitled to a
